Denosumab Discontinuation: the Abaloparatide plus Bisphosphonate Metronomic Sequential Approach
Background. Discontinuing denosumab (Dmab) causes a rapid increase in bone resorption, loss of bone mineral density (BMD), and clusters of rebound-associated vertebral fractures (RAFV). Current approaches, such as intravenous (IV) zoledronate (Zol), o
Authors
- Fanny Valsecchi (ORCID: https://orcid.org/0009-0006-2195-4585)
- Filippo Maria Bolamperti
- Alberto Vassallo (ORCID: https://orcid.org/0009-0004-8633-7700)
- Matteo Acanfora (ORCID: https://orcid.org/0009-0004-8362-9249)
Institutions
- IRCCS Ospedale San Raffaele (IT)
Publication Details
- Published
- 2025-09-02
- DOI
- https://doi.org/10.22541/au.175683892.26048418/v1
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05